866-997-4948(US-Canada Toll Free)

Global Overactive Bladder (OAB) Therapeutics Market Insights, Forecast to 2025

Published By :

QYResearch

Published Date : Sep 2018

Category :

Pharmaceutical

No. of Pages : 118 Pages

This report studies the global market size of Overactive Bladder (OAB) Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Overactive Bladder (OAB) Therapeutics in these regions.
This research report categorizes the global Overactive Bladder (OAB) Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

Overactive bladder is a medical syndrome, defined by urinary incontinence usually characterized by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination.
Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth.
In 2017, the global Overactive Bladder (OAB) Therapeutics market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Overactive Bladder (OAB) Therapeutics market based on company, product type, application and key regions.

The various contributors involved in the value chain of Overactive Bladder (OAB) Therapeutics include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Overactive Bladder (OAB) Therapeutics include
Allergan
Astellas Pharma
Hisamitsu Pharmaceutical
Pfizer
Ferring
GlaxoSmithKline
Ion Channel Innovations
Kwang Dong Pharmaceutical
Lanzhou Institute of Biological Products
Merck
ONO Pharmaceutical
Sanofi
Tengion
Teva Pharmaceutical Industries

Market Size Split by Type
Anticholinergic Agents
Beta-3 Adrenoreceptor Agonists
Market Size Split by Application
Hosptial
Clinci
Other

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Overactive Bladder (OAB) Therapeutics market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Overactive Bladder (OAB) Therapeutics market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Overactive Bladder (OAB) Therapeutics manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Overactive Bladder (OAB) Therapeutics with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Overactive Bladder (OAB) Therapeutics submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Overactive Bladder (OAB) Therapeutics are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Overactive Bladder (OAB) Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
1.1 Overactive Bladder (OAB) Therapeutics Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type
1.4.2 Anticholinergic Agents
1.4.3 Beta-3 Adrenoreceptor Agonists
1.5 Market by Application
1.5.1 Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application
1.5.2 Hosptial
1.5.3 Clinci
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Overactive Bladder (OAB) Therapeutics Market Size
2.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue 2016-2025
2.1.2 Global Overactive Bladder (OAB) Therapeutics Sales 2016-2025
2.2 Overactive Bladder (OAB) Therapeutics Growth Rate by Regions
2.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Regions
2.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
3.1.1 Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
3.1.2 Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers
3.1.3 Global Overactive Bladder (OAB) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers
3.2.1 Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2016-2018)
3.2.2 Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2016-2018)
3.3 Overactive Bladder (OAB) Therapeutics Price by Manufacturers
3.4 Overactive Bladder (OAB) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Overactive Bladder (OAB) Therapeutics Product Category
3.4.3 Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type
4.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type
4.3 Overactive Bladder (OAB) Therapeutics Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Overactive Bladder (OAB) Therapeutics Breakdown Data by Application

6 North America
6.1 North America Overactive Bladder (OAB) Therapeutics by Countries
6.1.1 North America Overactive Bladder (OAB) Therapeutics Sales by Countries
6.1.2 North America Overactive Bladder (OAB) Therapeutics Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Overactive Bladder (OAB) Therapeutics by Type
6.3 North America Overactive Bladder (OAB) Therapeutics by Application
6.4 North America Overactive Bladder (OAB) Therapeutics by Company

7 Europe
7.1 Europe Overactive Bladder (OAB) Therapeutics by Countries
7.1.1 Europe Overactive Bladder (OAB) Therapeutics Sales by Countries
7.1.2 Europe Overactive Bladder (OAB) Therapeutics Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Overactive Bladder (OAB) Therapeutics by Type
7.3 Europe Overactive Bladder (OAB) Therapeutics by Application
7.4 Europe Overactive Bladder (OAB) Therapeutics by Company

8 Asia Pacific
8.1 Asia Pacific Overactive Bladder (OAB) Therapeutics by Countries
8.1.1 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Countries
8.1.2 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Overactive Bladder (OAB) Therapeutics by Type
8.3 Asia Pacific Overactive Bladder (OAB) Therapeutics by Application
8.4 Asia Pacific Overactive Bladder (OAB) Therapeutics by Company

9 Central & South America
9.1 Central & South America Overactive Bladder (OAB) Therapeutics by Countries
9.1.1 Central & South America Overactive Bladder (OAB) Therapeutics Sales by Countries
9.1.2 Central & South America Overactive Bladder (OAB) Therapeutics Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Overactive Bladder (OAB) Therapeutics by Type
9.3 Central & South America Overactive Bladder (OAB) Therapeutics by Application
9.4 Central & South America Overactive Bladder (OAB) Therapeutics by Company

10 Middle East and Africa
10.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Countries
10.1.1 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Countries
10.1.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Type
10.3 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Application
10.4 Middle East and Africa Overactive Bladder (OAB) Therapeutics by Company

11 Company Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.1.4 Overactive Bladder (OAB) Therapeutics Product Description
11.1.5 Recent Development
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.2.4 Overactive Bladder (OAB) Therapeutics Product Description
11.2.5 Recent Development
11.3 Hisamitsu Pharmaceutical
11.3.1 Hisamitsu Pharmaceutical Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.3.4 Overactive Bladder (OAB) Therapeutics Product Description
11.3.5 Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Company Description
11.4.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.4.4 Overactive Bladder (OAB) Therapeutics Product Description
11.4.5 Recent Development
11.5 Ferring
11.5.1 Ferring Company Details
11.5.2 Company Description
11.5.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.5.4 Overactive Bladder (OAB) Therapeutics Product Description
11.5.5 Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 Company Description
11.6.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.6.4 Overactive Bladder (OAB) Therapeutics Product Description
11.6.5 Recent Development
11.7 Ion Channel Innovations
11.7.1 Ion Channel Innovations Company Details
11.7.2 Company Description
11.7.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.7.4 Overactive Bladder (OAB) Therapeutics Product Description
11.7.5 Recent Development
11.8 Kwang Dong Pharmaceutical
11.8.1 Kwang Dong Pharmaceutical Company Details
11.8.2 Company Description
11.8.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.8.4 Overactive Bladder (OAB) Therapeutics Product Description
11.8.5 Recent Development
11.9 Lanzhou Institute of Biological Products
11.9.1 Lanzhou Institute of Biological Products Company Details
11.9.2 Company Description
11.9.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.9.4 Overactive Bladder (OAB) Therapeutics Product Description
11.9.5 Recent Development
11.10 Merck
11.10.1 Merck Company Details
11.10.2 Company Description
11.10.3 Sales, Revenue and Gross Margin of Overactive Bladder (OAB) Therapeutics
11.10.4 Overactive Bladder (OAB) Therapeutics Product Description
11.10.5 Recent Development
11.11 ONO Pharmaceutical
11.12 Sanofi
11.13 Tengion
11.14 Teva Pharmaceutical Industries

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Overactive Bladder (OAB) Therapeutics Raw Material
13.1.2 Overactive Bladder (OAB) Therapeutics Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

List of Table

List of Tables and Figures

Figure Picture of Overactive Bladder (OAB) Therapeutics
Figure Global Overactive Bladder (OAB) Therapeutics Production (MT) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Overactive Bladder (OAB) Therapeutics Production Market Share by Types (Product Category) in 2017
Figure Anticholinergic Agents Product Picture
Table Major Manufacturers of Anticholinergic Agents
Figure Beta-3 Adrenoreceptor Agonists Product Picture
Table Major Manufacturers of Beta-3 Adrenoreceptor Agonists
Table Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application 2018-2025 (MT)
Figure Hosptial
Figure Clinci
Figure Other
Figure Overactive Bladder (OAB) Therapeutics Report Years Considered
Figure Global Overactive Bladder (OAB) Therapeutics Market Size 2016-2025 (Million US$)
Figure Global Overactive Bladder (OAB) Therapeutics Sales 2016-2025 (MT)
Table Global Overactive Bladder (OAB) Therapeutics Market Size by Regions 2016-2025 (MT) & (Million US$)
Table Global Overactive Bladder (OAB) Therapeutics Sales by Regions 2016-2025 (MT)
Table Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Regions 2016-2025
Figure Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Regions 2016-2025
Figure 2017 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Regions
Table Global Overactive Bladder (OAB) Therapeutics Revenue by Regions 2016-2025 (Million US$)
Table Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Regions 2016-2025
Figure Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Regions 2016-2025
Figure 2017 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Regions
Table Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2016-2018) (MT)
Table Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers (2016-2018)
Figure Global Overactive Bladder (OAB) Therapeutics Sales Share by Manufacturers in 2017
Table Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2016-2018) (Million US$)
Table Overactive Bladder (OAB) Therapeutics Revenue Share by Manufacturers (2016-2018)
Figure Overactive Bladder (OAB) Therapeutics Value Share by Manufacturers in 2017
Table Global Overactive Bladder (OAB) Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Overactive Bladder (OAB) Therapeutics Price (2016-2018) (USD/Kg)
Table Overactive Bladder (OAB) Therapeutics Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Overactive Bladder (OAB) Therapeutics Product Category
Table Date of International Manufacturers Enter into Overactive Bladder (OAB) Therapeutics Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table Global Overactive Bladder (OAB) Therapeutics Sales Share by Type (2016-2025)
Figure Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type in 2017
Table Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2016-2025) (Million US$)
Table Global Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2016-2025)
Figure Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2016-2025)
Figure Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type in 2017
Table Overactive Bladder (OAB) Therapeutics Price by Type 2013-2018 (USD/Kg)
Table Global Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table Global Overactive Bladder (OAB) Therapeutics Sales Share by Application (2016-2025)
Figure Global Sales Overactive Bladder (OAB) Therapeutics Market Share by Application (2016-2025)
Figure Global Sales Overactive Bladder (OAB) Therapeutics Market Share by Application (2016-2025)
Figure North America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2016-2025 (MT)
Figure North America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
Table North America Overactive Bladder (OAB) Therapeutics Sales by Countries (2016-2025) (MT)
Table North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries (2016-2025)
Figure 2017 North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries
Table North America Overactive Bladder (OAB) Therapeutics Revenue by Countries (2016-2025) (Million US$)
Table North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries (2016-2025)
Figure 2017 North America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries
Figure United States Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure United States Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Canada Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Canada Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Mexico Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Mexico Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Table North America Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure 2017 North America Overactive Bladder (OAB) Therapeutics Market Share by Type
Table North America Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2025)
Figure 2017 North America Overactive Bladder (OAB) Therapeutics Market Share by Application
Table North America Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2018) (MT)
Table North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Company (2016-2018)
Figure North America Overactive Bladder (OAB) Therapeutics Sales Market Share by Company in 2017
Figure Europe Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2016-2025 (MT)
Figure Europe Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
Table Europe Overactive Bladder (OAB) Therapeutics Sales by Countries (2016-2025) (MT)
Table Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries (2016-2025)
Figure 2017 Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries
Table Europe Overactive Bladder (OAB) Therapeutics Revenue by Countries (2016-2025) (Million US$)
Table Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries (2016-2025)
Figure 2017 Europe Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries
Figure Germany Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Germany Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (MT)
Figure France Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure France Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (MT)
Figure UK Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure UK Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Italy Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Italy Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Russia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Russia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Table Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure 2017 Europe Overactive Bladder (OAB) Therapeutics Market Share by Type
Table Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2025)
Figure 2017 Europe Overactive Bladder (OAB) Therapeutics Market Share by Application
Table Europe Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2018) (MT)
Table Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Company (2016-2018)
Figure Europe Overactive Bladder (OAB) Therapeutics Sales Market Share by Company in 2017
Figure Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2016-2025 (MT)
Figure Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Countries (2016-2025) (MT)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue by Countries (2016-2025) (Million US$)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries
Figure China Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure China Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Japan Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Japan Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Korea Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Korea Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure India Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure India Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Australia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Australia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Indonesia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Indonesia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Malaysia Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Malaysia Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Philippines Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Philippines Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Thailand Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Thailand Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Vietnam Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Vietnam Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Singapore Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Singapore Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure 2017 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Share by Type
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2025)
Figure 2017 Asia Pacific Overactive Bladder (OAB) Therapeutics Market Share by Application
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2018) (MT)
Table Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Company (2016-2018)
Figure Asia Pacific Overactive Bladder (OAB) Therapeutics Sales Market Share by Company in 2017
Figure Central & South America Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2016-2025 (MT)
Figure Central & South America Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales by Countries (2016-2025) (MT)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries (2016-2025)
Figure 2017 Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries
Table Central & South America Overactive Bladder (OAB) Therapeutics Revenue by Countries (2016-2025) (Million US$)
Table Central & South America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries (2016-2025)
Figure 2017 Central & South America Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries
Figure Brazil Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Brazil Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Argentina Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Argentina Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure 2017 Central & South America Overactive Bladder (OAB) Therapeutics Market Share by Type
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2025)
Figure 2017 Central & South America Overactive Bladder (OAB) Therapeutics Market Share by Application
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2018) (MT)
Table Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Company (2016-2018)
Figure Central & South America Overactive Bladder (OAB) Therapeutics Sales Market Share by Company in 2017
Figure Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate 2016-2025 (MT)
Figure Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Growth Rate 2016-2025 (Million US$)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Countries (2016-2025) (MT)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Countries
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue by Countries (2016-2025) (Million US$)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Overactive Bladder (OAB) Therapeutics Revenue Market Share by Countries
Figure GCC Countries Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure GCC Countries Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Turkey Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Turkey Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure Egypt Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure Egypt Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Figure South Africa Overactive Bladder (OAB) Therapeutics Sales Growth Rate (2016-2025) (MT)
Figure South Africa Overactive Bladder (OAB) Therapeutics Revenue Growth Rate (2016-2025) (Million US$)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Type (2016-2025) (MT)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2016-2025)
Figure 2017 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Type
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Application (2016-2025) (MT)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2016-2025)
Figure 2017 Middle East and Africa Overactive Bladder (OAB) Therapeutics Market Share by Application
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales by Company (2016-2018) (MT)
Table Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Company (2016-2018)
Figure Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales Market Share by Company in 2017
Table Allergan Company Details
Table Allergan Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Allergan Recent Development
Table Astellas Pharma Company Details
Table Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Astellas Pharma Recent Development
Table Hisamitsu Pharmaceutical Company Details
Table Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Hisamitsu Pharmaceutical Recent Development
Table Pfizer Company Details
Table Pfizer Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Pfizer Recent Development
Table Ferring Company Details
Table Ferring Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Ferring Recent Development
Table GlaxoSmithKline Company Details
Table GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table GlaxoSmithKline Recent Development
Table Ion Channel Innovations Company Details
Table Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Ion Channel Innovations Recent Development
Table Kwang Dong Pharmaceutical Company Details
Table Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Kwang Dong Pharmaceutical Recent Development
Table Lanzhou Institute of Biological Products Company Details
Table Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Lanzhou Institute of Biological Products Recent Development
Table Merck Company Details
Table Merck Overactive Bladder (OAB) Therapeutics Sales (MT), Revenue (Million US$), Price (USD/Kg) and Gross Margin (2016-2018)
Table Merck Recent Development
Table ONO Pharmaceutical Company Details
Table Sanofi Company Details
Table Tengion Company Details
Table Teva Pharmaceutical Industries Company Details
Figure GDP by Regions / Largest Economies Pie Chart in 2016
Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
Figure Saving Rate Total, % of GDP, 2015
Table Overactive Bladder (OAB) Therapeutics Value Chain
Table Typical Suppliers of Key Overactive Bladder (OAB) Therapeutics Raw Material
Table Overactive Bladder (OAB) Therapeutics Customers List
Table Overactive Bladder (OAB) Therapeutics Sales Channels
Table Overactive Bladder (OAB) Therapeutics Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *